Inovio Pharmaceuticals Inc (NASDAQ:INO) is slated to announce its Q3 2020 earnings on Friday, November 6, and analysts are eager to see whether it will outshine its performance in the previous quarter.
Inovio released its Q2 2020 earnings in August, revealing a loss of ($0.83) earnings per share which was off the mark from the estimated ($0.17) EPS. The company’s revenue for the quarter was $0.20 million which undershot the $2.61 million analyst estimate. This poor performance was largely attributed to the coronavirus pandemic’s impact on the company’s performance.
The Q2 2020 earnings may have been below the mark but analysts believe that the Q3 results will show significant improvements especially with economic performance slowly getting back on its feet. Analysts also expect this to be the case and this is why the current consensus estimate for Inovio’s sales is 3.05 million in Q3 2020. They also expect the company to report negative operating income at -31.2 million. Analysts also expect the company to report a ($0.19) EPS which will be lower than the ($0.83) EPS reported in the previous year.
Why do analysts expect Inovio to report better performance in Q3?
Inovio’s performance in Q2 2020 was undoubtedly affected by the coronavirus and the resulting economic restrictions. Drug pipelines and sales took a hit, and this explains the declining performance in Q2. However, the economic reopening is expected to provide a boost to the company’s performance even though the figures might not be as expected.
Inovio is one of the companies that have been developing a COVID-19 vaccine although it has encountered challenges like many companies that are also working on a vaccine for the pandemic. The company has also been working on other programs such as the development of therapies for infectious diseases, cancers, and HPV. It is currently pursuing the development of a treatment for the Zika virus. The company focuses on the development of DNA-based approaches to therapies for various medical conditions.